Alpine Immune Sciences Inc.

8.70-0.4300-4.71%Vol 429.44K1Y Perf -6.07%
Jun 24th, 2022 16:00 DELAYED
BID6.00 ASK9.00
Open9.30 Previous Close9.13
Pre-Market- After-Market8.70
 - -  - -%
Target Price
20.00 
Analyst Rating
Strong Buy 1.00
Potential %
129.89 
Finscreener Ranking
★★★     50.06
Insiders Trans % 3/6/12 mo.
-/-/-17 
Value Ranking
★+     42.79
Insiders Value % 3/6/12 mo.
-/-/9 
Growth Ranking
★★★★     57.46
Insiders Shares Cnt. % 3/6/12 mo.
-/-/9 
Income Ranking
 —    -
Price Range Ratio 52W %
32.14 
Earnings Rating
Strong Buy
Market Cap263.85M 
Earnings Date
9th Aug 2022
Alpha0.01 Standard Deviation0.28
Beta1.74 

Today's Price Range

8.549.37

52W Range

6.0014.40

5 Year PE Ratio Range

-5.80-1.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-0.80%
1 Month
2.23%
3 Months
-9.94%
6 Months
-36.73%
1 Year
-6.07%
3 Years
93.33%
5 Years
-7.05%
10 Years
-

TickerPriceChg.Chg.%
ALPN8.70-0.4300-4.71
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
2.50
2.60
0.10
0.16
-61.80
Leverage Ratio 2.20
ProfitabilityValueIndustryS&P 500US Markets
-
-137.40
-135.70
-1 746.90
-
RevenueValueIndustryS&P 500US Markets
33.87M
1.12
256.15
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.17-0.25-47.06
Q04 2021-0.26-0.52-100.00
Q03 20210.01-0.55-5 600.00
Q02 2021-0.29-0.46-58.62
Q01 2021-0.32-0.45-40.62
Q04 2020-0.27-0.270.00
Q03 2020-0.23-0.28-21.74
Q02 2020-0.23-0.53-130.43
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.3925.00Positive
9/2022 QR-0.10-300.00Negative
12/2022 FY-0.92-58.62Negative
12/2023 FY-1.69-4.32Negative
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.39
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume429.44K
Shares Outstanding30.33K
Shares Float15.50M
Trades Count1.74K
Dollar Volume3.76M
Avg. Volume127.70K
Avg. Weekly Volume147.83K
Avg. Monthly Volume128.01K
Avg. Quarterly Volume107.25K

Alpine Immune Sciences Inc. (NASDAQ: ALPN) stock closed at 8.7 per share at the end of the most recent trading day (a -4.71% change compared to the prior day closing price) with a volume of 429.44K shares and market capitalization of 263.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Alpine Immune Sciences Inc. CEO is Mitchell H. Gold.

The one-year performance of Alpine Immune Sciences Inc. stock is -6.07%, while year-to-date (YTD) performance is -37.18%. ALPN stock has a five-year performance of -7.05%. Its 52-week range is between 6 and 14.4, which gives ALPN stock a 52-week price range ratio of 32.14%

Alpine Immune Sciences Inc. currently has a PE ratio of -4.90, a price-to-book (PB) ratio of 2.30, a price-to-sale (PS) ratio of 7.85, a price to cashflow ratio of 38.50, a PEG ratio of 2.32, a ROA of -26.48%, a ROC of -44.68% and a ROE of -56.97%. The company’s profit margin is -%, its EBITDA margin is -135.70%, and its revenue ttm is $33.87 Million , which makes it $1.12 revenue per share.

Of the last four earnings reports from Alpine Immune Sciences Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.39 for the next earnings report. Alpine Immune Sciences Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Alpine Immune Sciences Inc. is Strong Buy (1), with a target price of $20, which is +129.89% compared to the current price. The earnings rating for Alpine Immune Sciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alpine Immune Sciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alpine Immune Sciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.15, ATR14 : 0.56, CCI20 : -26.70, Chaikin Money Flow : -0.10, MACD : 0.07, Money Flow Index : 57.55, ROC : -3.33, RSI : 48.64, STOCH (14,3) : 36.36, STOCH RSI : 0.30, UO : 48.32, Williams %R : -63.64), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alpine Immune Sciences Inc. in the last 12-months were: Christopher Peetz (Buy at a value of $19 323), Jay Venkatesan (Sold 400 000 shares of value $3 760 000 ), Mitchell H. Gold (Sold 468 466 shares of value $4 445 157 ), Peter A. Thompson (Buy at a value of $9 499 987), Robert E. Conway (Buy at a value of $249 120)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Alpine Immune Sciences Inc.

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202.

CEO: Mitchell H. Gold

Telephone: +1 206 788-4545

Address: 188 East Blaine Street, Seattle 98102, WA, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

76%24%

Bearish Bullish

74%26%

Bearish Bullish

65%35%

TipRanks News for ALPN

Fri, 18 Mar 2022 10:19 GMT Alpine Immune Sciences (ALPN) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Fri, 04 Feb 2022 11:26 GMT Alpine Immune Sciences (ALPN) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits